BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lim R, Sun Y, Im SA, Hsieh RK, Yau TK, Bonaventura A, Cheirsilpa A, Esser R, Mueser M, Advani S. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study. World J Gastroenterol 2011; 17(14): 1879-1888 [PMID: 21528063 DOI: 10.3748/wjg.v17.i14.1879]
URL: https://www.wjgnet.com/1007-9327/full/v17/i14/1879.htm
Number Citing Articles
1
Michael B. Tomblyn, Bryan H. Goldman, Charles R. Thomas, Jacqueline K. Benedetti, Heinz-Josef Lenz, Vivek Mehta, Thaddeus Beeker, Philip J. Gold, James L. Abbruzzese, Charles D. Blanke. Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)Journal of Thoracic Oncology 2012; 7(5): 906 doi: 10.1097/JTO.0b013e31824c7bed
2
Richard M. Goldberg, Clara Montagut, Zev A. Wainberg, Philippe Ronga, Françis Audhuy, Julien Taieb, Sebastian Stintzing, Salvatore Siena, Daniele Santini. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancerESMO Open 2018; 3(4): e000353 doi: 10.1136/esmoopen-2018-000353
3
C.F. Jehn, L. Böning, H. Kröning, A. Pezzutto, D. Lüftner. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancerEuropean Journal of Cancer 2014; 50(7): 1269 doi: 10.1016/j.ejca.2014.01.005
4
Robert J. Cersosimo. Management of advanced colorectal cancer, part 2American Journal of Health-System Pharmacy 2013; 70(6): 491 doi: 10.2146/ajhp110532b
5
Benny Vittrup Jensen, Jakob V. Schou, Mette Yilmaz, Helle H. Johannesen, Kristin Skougaard, Dorte Linnemann, Estrid V. Hogdall, Finn O. Larsen, Julia S. Johansen, Per Pfeiffer, Dorte L. Nielsen. Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation statusInternational Journal of Cancer 2021; 148(10): 2542 doi: 10.1002/ijc.33448
6
Florinda A. Santos, Rui Manuel Reis, Lucas C. Barroti, Allan A. L. Pereira, Marcus M. Matsushita, Ana Carolina de Carvalho, José Guilherme Datorre, Gustavo N. Berardinelli, Raphael L. C. Araujo. Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal CancerJournal of Gastrointestinal Cancer 2024; 55(1): 344 doi: 10.1007/s12029-023-00964-x
7
Zev A. Wainberg, Maria Alsina, Heloisa P. Soares, Irene Braña, Carolyn D. Britten, Gianluca Del Conte, Patrick Ezeh, Brett Houk, Kenneth A. Kern, Stephen Leong, Nuzhat Pathan, Kristen J. Pierce, Lillian L. Siu, Jennifer Vermette, Josep Tabernero. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced CancerTargeted Oncology 2017; 12(6): 775 doi: 10.1007/s11523-017-0530-5
8
D. Gomez, A. De Rosa, A. Addison, A. Brooks, H.Z. Malik, I.C. Cameron. Cetuximab therapy in the treatment of metastatic colorectal cancer: The future frontier?International Journal of Surgery 2013; 11(7): 507 doi: 10.1016/j.ijsu.2013.04.014
9
Dong Ju Son, Ji Eun Hong, Jung Ok Ban, Ju Ho Park, Hye Lim Lee, Sun Mi Gu, Jae Yeon Hwang, Myung Hee Jung, Dong Won Lee, Sang-Bae Han, Jin Tae Hong. Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell GrowthviaInhibition of the ERK-Dependent EGF Receptor Signaling PathwayBioMed Research International 2015; 2015: 1 doi: 10.1155/2015/397563
10
Carsten Bokemeyer, Fortunato Ciardiello, Olivier Dubreuil, Joel Guigay, Stefan Kasper, Per Pfeiffer, Carmine Pinto, Kensei Yamaguchi, Takayuki Yoshino, Christoph Zielinski, Regina Esser, Josep Tabernero. Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration ScheduleFuture Oncology 2024; 20(7): 393 doi: 10.2217/fon-2023-0282
11
S. Abdelwahab, A. Azmy, H. Abdel-aziz, H. Salim, A. Mahmoud. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)Journal of Cancer Research and Clinical Oncology 2012; 138(9): 1487 doi: 10.1007/s00432-012-1229-8
12
Gerald W. Prager, Matthias Unseld, Fredrik Waneck, Robert Mader, Fritz Wrba, Markus Raderer, Thorsten Fuereder, Phillip Staber, Ulrich Jäger, Markus Kieler, Daniela Bianconi, Mir Alireza Hoda, Lukas Baumann, Alexander Reinthaller, Walter Berger, Christoph Grimm, Heinz Kölbl, Maria Sibilia, Leonhard Müllauer, Christoph Zielinski. Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncologyOncotarget 2019; 10(9): 942 doi: 10.18632/oncotarget.26604
13
Suzannah J Chapman, Daniel McKavanagh, Matthew E Burge, Ian McPherson, Euan Walpole, Samantha A Hollingworth. Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in QueenslandAsia-Pacific Journal of Clinical Oncology 2017; 13(5) doi: 10.1111/ajco.12518
14
Jesús García-Foncillas, Yu Sunakawa, Dan Aderka, Zev Wainberg, Philippe Ronga, Pauline Witzler, Sebastian Stintzing. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid TumorsFrontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00849
15
Hao Zhuang, Zhen-yi Xue, Lu Wang, Xiao-yan Li, Ning Zhang, Rong-xin Zhang. Efficacy and immune mechanisms of cetuximab for the treatment of metastatic colorectal cancerClinical Oncology and Cancer Research 2011; 8(4): 207 doi: 10.1007/s11805-011-0582-8